Project Grant R01HL187428
Award Date 8/20/26
Completion Date 5/31/31
Dollars Obligated $691K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97201, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Oregon Health & Science University $2,141,996 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and implement Community Vital Signs (CVS) strategies for identifying undiagnosed hypertension in Nigeria. The project adapts community-based screening interventions to increase blood pressure screening among adults over 18 years of age and connect patients to primary care for hypertension...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $672,958 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on task-shifting models for hypertension care in low-resource rural settings. The research project, titled "Task-Shifting at the Doorstep of the People: Strengthening the Hypertension Care Continuum Within Primary Health Care in a Low-Resource Setting," develops and tests...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $769,799 in project grant funding (R01HL184132) on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds a comparative analysis of cardiovascular disease incidence, management, and outcomes between rural and urban Americans using administrative claims data from MarketScan and the Medicare 20% sample. The research will classify enrollees by rural-urban...
- The National Heart, Lung, and Blood Institute awarded The Johns Hopkins University $1,507,442 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate pulse oximeter accuracy and its impact on clinical outcomes in hospitalized patients. The ENHANCE-O2 project conducts a retrospective cohort study matching concurrent pulse oximeter readings with gold-standard arterial oxygen saturation measurements in patients with shock and acute exacerbation of COPD. The...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of California, San Francisco $2,493,062 on September 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine implementation, effectiveness, and cost-effectiveness of two strategies for integrating community health worker-facilitated hypertension telehealth into routine primary health centers operated by Kenya's Ministry of Health. The study compares a core implementation...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Talk Story Health LLC $550,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026. Talk Story Health LLC will develop and test BEAT-TO-BEAT, an AI-powered digital health intervention designed to improve cardiovascular health outcomes in rural communities with limited healthcare access. The project delivers three interconnected components: a Cardiovascular Information Engine (CIE) trained on validated...
- The National Heart, Lung, and Blood Institute awarded Environment & Health Group Inc. $314,321 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop HeartSense.AI, a generative AI-driven mobile health solution for hypertension self-management in lower-income adults. The application describes an mHealth platform that integrates a generative AI model with home-based blood pressure monitoring, digital pill reminders, and non-physician-led telehealth to...
- The National Heart Lung and Blood Institute awarded Brown University $350,000 on August 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to catalog and characterize outpatient cardiology practices acquired by private equity firms between 2019 and 2025, and to examine effects of those acquisitions on low-value cardiovascular care delivery and patient outcomes using a quasi-experimental difference-in-differences design. The research will track private equity...